MMS22L and neoplasm: Tumors with heterozygous or homozygous deletion had significantly lower MMS22L mRNA levels compared to those with wild-type MMS22L. Patients with lower MMS22L expression had a shorter survival (Fig. 4g), suggesting tumor progression driven by HRD-mediated genomic instability.